Can tucatinib be used in combination with monoclonal antibodies?

In some cases, tucatinib may be combined with trastuzumab RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer, in combination with trastuzumab and capecitabine as a triple therapy for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases. The two drugs are targeted drugs for HER2-positive metastatic breast cancer. This triple therapy is called T-DM1 follow-up therapy. Its recommended dose is 300mg, taken orally twice a day. When using the combination, the doctor's prescription information and drug interactions need to be considered.